This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

Nine years on from securing $3.84 million for a phase I clinical trial to test the formulation, with results showing it ...

Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by ...

The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom ...

PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia. The Boston, Massachusetts-based biotechnology company said the milestone ...

Scientists comment on the FDA approving Cobenfy (KarXT) for schizophrenia. Dr Sameer Jauhar, Senior Clinical Lecturer in Affective Disorders and Psychosis, Consultant Psychiatrist, King’s College, ...

Bristol-Myers wins FDA nod for novel antipsychotic. DirecTV, Dish close in on merger to form largest US pay-TV service: ...

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.

Stock futures dipped early Friday morning as investors geared up to closely monitor new personal spending and inflation data. These economic indicators could of ...

They called their experimental drug KarXT, and shepherded it through clinical trials to prove its safety and effectiveness.